Fujifilm Invests in VALANX Biotech to Strengthen ADC CDMO Capabilities

CAR-T Digest - August 2020

12 March 2026: Fujifilm invests in VALANX Biotech to strengthen ADC CDMO capabilities

Fujifilm announced an investment in Austrian biotechnology company VALANX Biotech to strengthen its contract development and manufacturing organization (CDMO) capabilities in the rapidly growing antibody-drug conjugate field
Through this strategic investment, Fujifilm aims to collaborate with VALANX on advanced ADC manufacturing technologies, leveraging the company’s proprietary Golden Site Technology that enables highly site-specific conjugation through the incorporation of synthetic amino acids into antibodies
This technology allows precise control over conjugation sites and drug-to-antibody ratios, improving ADC uniformity, stability, and overall therapeutic performance while also supporting the development of VALANX’s own ADC pipeline
The investment aligns with Fujifilm’s broader strategy to establish ADCs as a key modality within its life sciences business and to build end-to-end manufacturing capabilities across antibodies, linkers and payloads, conjugation, and formulation
As part of this strategy, Fujifilm plans to launch Japan’s first fully integrated ADC manufacturing services at FUJIFILM Toyama Chemical by 2027 while expanding linker and payload production through FUJIFILM Wako Pure Chemical, reinforcing its ambition to become a global hub for ADC manufacturing and innovation